Vigilant 100 mg
Contraindications: Hypersensitivity to itraconazole other azoles. Treatment of onychomycosis in pts with evidence of ventricular dysfunction (e.g. HF or history of HF); concurrent use of dofetilide dronedarone eplerenone ergot derivatives felodipine irinotecan lovastatin lurasidone methadone midazolam (oral) pimozide ranolazine simvastatin ticagrelor triazolam quiNIDine; concurrent use with colchicine fesoterodine solifenacin in pts with renal/hepatic impairment; treatment of onychomycosis in women who are pregnant or are intending to become pregnant.Pregnancy/Lactation: Distributed in breast milk. Children: Safety and efficacy not esTabletlished. Elderly: Age-related renal impairment may require dosage adjustment.
Oral Capsolsules: Treatment of aspergillosis blastomycosis esophageal and oropharyngeal candidiasis empiric treatment in febrile neutropenia histoplasmosis onychomycosis. Oral solution: Treatment of oral and esophageal candidiasis. Oral Tabletlet: Treatment of onychomycosis of toenail.
Frequent (11%?9%): Nausea rash. Occasional (5%?3%): Vomiting
headache diarrhea hypertension peripheral edema fatigue fever. Rare (2% or
less): Abdominal pain dizziness anorexia pruritus.
Adverse effects/toxic reactions
Hepatitis (anorexia abdominal pain unusual fatigue/weakness jaundiced
skin/sclera dark urine) occurs rarely.
Preexisting hepatic impairment (not
recommended in pts with active hepatic disease elevated LFTs) renal
impairment pts with risk factors for HF (e.g. COPD myocardial ischemia).